ATE544463T1 - Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen - Google Patents

Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen

Info

Publication number
ATE544463T1
ATE544463T1 AT05851326T AT05851326T ATE544463T1 AT E544463 T1 ATE544463 T1 AT E544463T1 AT 05851326 T AT05851326 T AT 05851326T AT 05851326 T AT05851326 T AT 05851326T AT E544463 T1 ATE544463 T1 AT E544463T1
Authority
AT
Austria
Prior art keywords
scf
treatment
polypeptide
brain
combination
Prior art date
Application number
AT05851326T
Other languages
English (en)
Inventor
Li-Ru Zhao
John Kessler
Seema Singhal
Mehta Jayesh
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Application granted granted Critical
Publication of ATE544463T1 publication Critical patent/ATE544463T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05851326T 2004-11-05 2005-11-04 Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen ATE544463T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62518904P 2004-11-05 2004-11-05
PCT/US2005/039792 WO2006055260A2 (en) 2004-11-05 2005-11-04 Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders

Publications (1)

Publication Number Publication Date
ATE544463T1 true ATE544463T1 (de) 2012-02-15

Family

ID=36407603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05851326T ATE544463T1 (de) 2004-11-05 2005-11-04 Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen

Country Status (6)

Country Link
US (2) US20060153799A1 (de)
EP (1) EP1817047B1 (de)
AT (1) ATE544463T1 (de)
AU (1) AU2005306894B2 (de)
CA (1) CA2586365A1 (de)
WO (1) WO2006055260A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059010A2 (en) 2005-11-14 2007-05-24 Enterprise Partners Venture Capital Stem cell factor therapy for tissue injury
DE102006004142A1 (de) * 2006-01-27 2007-08-02 Axaron Bioscience Ag Neue therapeutische Indikationen von Koloniestimulierenden Faktoren
US9770485B2 (en) * 2006-02-21 2017-09-26 Academia Sinica Methods for rescuing learning and/or memory deficits caused by alzheimer's disease by G-CSF
US7618938B2 (en) * 2007-02-07 2009-11-17 Academia Sinica Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly
US20110142795A1 (en) * 2008-08-05 2011-06-16 University Of South Florida Methods of treating cognitive impairment
US9132168B2 (en) 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
KR20100020125A (ko) * 2008-08-12 2010-02-22 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 신경병증성 통증 예방 또는치료제
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
US9642917B2 (en) 2011-07-25 2017-05-09 Generon (Shanghai) Corporation, Ltd. Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases
CN107267449B (zh) 2013-02-06 2021-03-19 Nc医学研究公司 用于治疗神经变性的细胞疗法
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
US10039808B2 (en) * 2014-10-22 2018-08-07 Michael Chez Method of treating or improving neurological function in a human subject
US9925244B1 (en) 2015-02-17 2018-03-27 Michael Chez Treatment of warts in non-immunosuppressed patients
WO2023158681A1 (en) * 2022-02-16 2023-08-24 Vasogenesis Inc. Methods of using a blood cell growth factor to treat impaired blood flow

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
AU7675487A (en) 1986-08-11 1988-05-19 Cetus Corporation Expression of granulocyte colony-stimulating factor
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
DE68929566D1 (de) 1988-05-13 2010-01-28 Amgen Inc Verfahren zur Isolierung und Reinigung von G-CSF
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE464482C (sv) 1989-08-25 1997-09-08 Teknoskand Invent Ab Med spärr försett svängarmsbeslag till fönster, luckor o d
EP0447523A4 (en) 1989-10-10 1991-11-27 Amgen Inc. Compositions and methods for treating or preventing infections in canine and feline animals
US6204363B1 (en) * 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
WO1991005795A1 (en) 1989-10-16 1991-05-02 Amgen Inc. Stem cell factor
US6207454B1 (en) * 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
SG59931A1 (en) * 1989-10-16 1999-02-22 Amgen Inc Stem cell factor
US6248319B1 (en) * 1989-10-16 2001-06-19 Krisztina M. Zsebo Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
JPH04164098A (ja) 1990-03-07 1992-06-09 Kirin Amgen Inc 化学修飾顆粒球コロニー刺激因子誘導体
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US5241072A (en) 1990-05-25 1993-08-31 Genzyne Corporation Oligosaccharide oxazolines, oligosaccharide conjugates and methods of preparation thereof
EP0536317A1 (de) 1990-06-25 1993-04-14 Immunex Corporation Wachstumsfaktor der mastzellen
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
AU651152B2 (en) 1990-08-29 1994-07-14 Genetics Institute, Llc Multidomain hematopoiesis stimulators
JPH05502463A (ja) 1990-09-28 1993-04-28 オーソ・フアーマシユーチカル・コーポレーシヨン ハイブリツド成長因子
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
JPH06510202A (ja) 1991-08-30 1994-11-17 フレッド・ハッチンソン・キャンサー・リサーチ・センター ハイブリッドサイトカイン
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
IL112583A0 (en) 1994-02-08 1995-05-26 Amgen Inc Oral delivery of chemically modified proteins
US5525708A (en) 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
EP1019082B2 (de) 1997-10-02 2008-06-04 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Verwendung eines kolonie-stimulierenden faktors (csf) zum verstärken des kollateralen wachstums von kollateralen arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
KR100773323B1 (ko) 2000-01-10 2007-11-05 맥시겐 홀딩스 리미티드 지-씨에스에프 접합체
DE10033219A1 (de) * 2000-07-07 2002-01-24 Univ Heidelberg Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF)
CA2452582C (en) 2001-07-11 2013-01-22 Maxygen Holdings, Ltd. G-csf conjugates
WO2003030821A2 (en) 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003069310A2 (en) * 2002-02-14 2003-08-21 Buck Institute Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia
WO2004021992A2 (en) * 2002-09-06 2004-03-18 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors

Also Published As

Publication number Publication date
AU2005306894A1 (en) 2006-05-26
AU2005306894B2 (en) 2011-11-24
WO2006055260A2 (en) 2006-05-26
US8524655B2 (en) 2013-09-03
EP1817047B1 (de) 2012-02-08
WO2006055260A3 (en) 2006-07-27
US20060153799A1 (en) 2006-07-13
US20100286039A1 (en) 2010-11-11
CA2586365A1 (en) 2006-05-26
EP1817047A2 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
ATE544463T1 (de) Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
DE602005015002D1 (de) Methylendipiperidinderivate
ATE545422T1 (de) Beta-glycolipide als immunomodulatoren
EA201270591A1 (ru) ДВУЗАМЕЩЕННЫЕ ОКТАГИДРОПИРРОЛ[3,4-c]ПИРРОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРЕКСИНОВЫХ РЕЦЕПТОРОВ
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2008021196A3 (en) Methods and compositions for the treatment of medical disorders
DK1709161T3 (da) Humane terapeutiske celler, som udskiller nervevækstfaktor
WO2007047978A3 (en) Modulation of neurogenesis by pde inhibition
WO2008083204A3 (en) Modulation of neurogenesis by melatoninergic ligands
WO2007134077A3 (en) 5 ht receptor mediated neurogenesis
WO2007098089A3 (en) Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
WO2007098091A3 (en) Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
IL180725A0 (en) Inhibitors of angiopoietin-like 4 protein, combinations, and their use
WO2006073484A3 (en) Treating inflammatory disorders by electrical vagus nerve stimulation
EA200900874A1 (ru) Применение эритропоэтина в низкой дозировке для стимуляции эндотелиальных клеток-предшественников, а также для регенерации органов и замедления прогрессирования повреждений конечных органов
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
TW200744629A (en) Treatments for neurological disorders
WO2005030240A3 (en) Vege-cor vege-d materials and methods for stimulation of neural stem cells
WO2005079848A3 (en) Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders
AR036401A1 (es) Incremento de la cantidad de celulas madre neuronales inducido por prolactina.
WO2008011083A9 (en) Compounds for enhancing arginase activity and methods of use thereof
NZ741780A (en) Anti-htra1 antibodies and methods of use thereof
WO2006023452A3 (en) Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases